Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir discontinuation was assessed and analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Cusato, Jessica, Borghetti, Alberto, Teti, Elisabetta, Milesi, Maurizio, Tettoni, Maria Cristina, Bonora, Stefano, Trunfio, Mattia, D’Avolio, Antonio, Compagno, Mirko, Di Giambenedetto, Simona, Di Perri, Giovanni, Calcagno, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781993/
https://www.ncbi.nlm.nih.gov/pubmed/36557240
http://dx.doi.org/10.3390/metabo12121202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781993/
https://www.ncbi.nlm.nih.gov/pubmed/36557240
http://dx.doi.org/10.3390/metabo12121202

Ejemplares similares